Evidence map›Paper›PMID 42894086›Full record

ArticleNeurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology2026

Cerebrospinal fluid positive for SARS-CoV-2 associated with neurological manifestations and proteome alterations in a multiple myeloma patient.

Jayr Schmidt-Filho, Thais Rodrigues B Geraldo, Victor C Carregari, Marina de Mattos Nascimento, Anita Cassoli Cortez, Ramon Teixeira Costa, Ivan Leonardo Avelino Franca-Silva, Israel Tojal da Silva, Marcos Aurélio Peterlevitz, Alessandro S Farias and 11 more

Abstract readCase Reports
In one paragraph

Article in Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors.

Jayr Schmidt-FilhoDepartment of Hematology and Cell Therapy, A.C.Camargo Cancer Center, São Paulo, SP, Brazil.
Thais Rodrigues B GeraldoDepartment of Neurology, A.C.Camargo Cancer Center, São Paulo, Brazil.
Victor C CarregariLaboratory of Neuroproteomics, Department of Biochemistry and Tissue Biology, Institute of Biology, University of Campinas (UNICAMP), Campinas, Brazil.
Marina de Mattos NascimentoDepartment of Hematology and Cell Therapy, A.C.Camargo Cancer Center, São Paulo, SP, Brazil.
Anita Cassoli CortezDepartment of Hematology and Cell Therapy, A.C.Camargo Cancer Center, São Paulo, SP, Brazil.
Ramon Teixeira CostaIntensive Care Unit, A.C.Camargo Cancer Center, São Paulo, Brazil.
Ivan Leonardo Avelino Franca-SilvaDepartment of Infectious Diseases and Infection Control, A.C.Camargo Cancer Center, R. Prof. Antônio Prudente, 211 - Liberdade, São Paulo, SP, 01509-010, Brazil.
Israel Tojal da SilvaLaboratory of Computational Biology, A.C.Camargo Cancer Center, São Paulo, Brazil.
Marcos Aurélio PeterlevitzDepartment of Neurology, A.C.Camargo Cancer Center, São Paulo, Brazil.
Alessandro S FariasExperimental Medicine Research Cluster (EMRC), University of Campinas (UNICAMP), Campinas, SP, Brazil.
José Eduardo Vitorino GalonDepartment of Neurology, A.C.Camargo Cancer Center, São Paulo, Brazil.
Ana Maria FragaLaboratory of Virology, Grupo Fleury, São Paulo, Brazil.
Celso Francisco Hernandes GranatoLaboratory of Virology, Grupo Fleury, São Paulo, Brazil.
Gislaine Cristina Lopes Machado PortoDepartment of Imaging, A.C.Camargo Cancer Center, São Paulo, Brazil.
Diana Noronha NunesLaboratory of Medical Genomics, A.C.Camargo Cancer Center, São Paulo, Brazil.
Dirce Maria CarraroTranslational Immuno-oncology Group, International Research Center, A.C. Camargo Cancer Center, São Paulo, Brazil.
Kenneth J GollobD'Or Institute for Research and Education (IDOR), São Paulo, Brazil.
Emmanuel Dias-NetoLaboratory of Medical Genomics, A.C.Camargo Cancer Center, São Paulo, Brazil.
Daniel Martins-de-SouzaLaboratory of Neuroproteomics, Department of Biochemistry and Tissue Biology, Institute of Biology, University of Campinas (UNICAMP), Campinas, Brazil.
Vilma R MartinsINCT in Modelling Human Complex Diseases With 3D Platforms (Model3D), São Paulo, Brazil.
Marjorie Vieira BatistaReference Center for Hematologic Neoplasms at the A.C.Camargo Cancer Center, São Paulo, Brazil. marjorie.batista@accamargo.org.br.ORCID http://orcid.org/0000-0002-2141-6879

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAlthough SARS-CoV-2 infection is primarily associated with respiratory symptoms, neurological complications have been increasingly recognized, even in the absence of pulmonary involvement. CASE PRESENTATION: We report a case of a 67-year-old woman with a history of multiple myeloma and recent exposure to a COVID-19-positive individual who developed rapidly progressive neurological symptoms, including dysarthria, dysphagia, and hypoesthesia, without any respiratory manifestations. Her condition deteriorated to focal and dyscognitive status epilepticus, requiring mechanical ventilation. Brain MRI showed imaging features consistent with rhombencephalitis. SARS-CoV-2 infection was confirmed through positive qRT-PCR results from both nasopharyngeal swab and cerebrospinal fluid (CSF). Further analysis of the CSF using quantitative shotgun proteomics via mass spectrometry revealed a neuroinflammatory profile indicative of blood-brain barrier disruption and differential expression of several proteins relevant to brain function, including the major prion protein, superoxide dismutase 1 (SOD-1), and other aggregation-prone proteins.

conclusionsThis case supports the hypothesis that SARS-CoV-2 can invade the central nervous system and cause severe neurological impairment, even in the absence of typical respiratory symptoms. The findings underscore the importance of considering SARS-CoV-2 in the differential diagnosis of rapidly progressive neurological syndromes and highlight the need for further investigation into the mechanisms of neuroinvasion and the potential neurotropism of emerging viral variants.

Indexed as

Coronavirus InfectionsCOVID-19Multiple MyelomaNervous System DiseasesPneumonia, ViralProteomeAgedBetacoronavirusFemaleHumansProteomicsSARS-CoV-2ProteomeCNSCOVID-19CSFMass spectrometryMultiple myelomaNeurologicalProteomicSARS-CoV-2

Identifiers

PMID42894086
PMCPMC13677627

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.